Management of heparin-induced thrombocytopenia

Bibliography

• Warkentin TE. HIT paradigms and paradoxes. J Thromb Haemost 2011;9(Suppl 1):105-17
   PubMed Web of Science ®Google Scholar
• Amiral J, Bridey F, Dreyfus M, Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992;68:95-6
   PubMed Web of Science ®Google Scholar
• Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-Induced Thrombocytopenia. 4th edition. Informa Healthcare USA; New York: 2007. p. 21-66
   Google Scholar
• Greinacher A, Michels I, Liebenhoff U, Heparin-associated thrombocytopenia: immune complexes are attached to the platelet membrane by the negative charge of highly sulphated oligosaccharides. Br J Haematol 1993;84:711-16
   PubMed Web of Science ®Google Scholar
• Horne MK III. Nonimmune heparin-platelet interactions: implications for the pathogenesis of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-Induced Thrombocytopenia. 1st edition. Marcel Dekker, Inc.; New York: 2000. p. 113-26
   Google Scholar
• Gao C, Boylan B, Fang J, Heparin promotes platelet responsiveness by potentiating alphaIIbbeta3-mediated outside-in signaling. Blood 2011;117:4946-52
   PubMed Web of Science ®Google Scholar
• Kaplan KL, Broekman MJ, Chernoff A, Platelet alpha-granule proteins: studies on release and subcellular localization. Blood 1979;53:604-18
   PubMed Web of Science ®Google Scholar
• Rucinski B, Niewiarowski S, James P, Antiheparin proteins secreted by human platelets. purification, characterization, and radioimmunoassay. Blood 1979;53:47-62
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001;344:1286-92
   PubMed Web of Science ®Google Scholar
• Selleng K, Schutt A, Selleng S, Studies of the anti-platelet factor 4/heparin immune response: adapting the enzyme-linked immunosorbent spot assay for detection of memory B cells against complex antigens. Transfusion 2010;50:32-9
   PubMed Web of Science ®Google Scholar
• Greinacher A, Ittermann T, Bagemuhl J, Heparin-induced thrombocytopenia: towards standardization of platelet factor 4/heparin antigen tests. J Thromb Haemost 2010;8:2025-31
   PubMed Web of Science ®Google Scholar
• Hursting MJ, Pai PJ, McCracken JE, Platelet factor 4/heparin antibodies in blood bank donors. Am J Clin Pathol 2010;134:774-80
   PubMedGoogle Scholar
• Krauel K, Potschke C, Weber C, Platelet factor 4 binds to bacteria-inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood 2011;117:1370-8
   PubMed Web of Science ®Google Scholar
• Greinacher A, Holtfreter B, Krauel K, Association of natural anti-platelet factor 4/heparin antibodies with periodontal disease. Blood 2011;118:1395-401
   PubMed Web of Science ®Google Scholar
• Jay RM, Warkentin TE. Fatal heparin-induced thrombocytopenia (HIT) during warfarin thromboprophylaxis following orthopedic surgery: another example of ‘spontaneous' HIT? J Thromb Haemost 2008;6:1598-600
   PubMed Web of Science ®Google Scholar
• Pruthi RK, Daniels PR, Nambudiri GS, Warkentin TE. Heparin-induced thrombocytopenia (HIT) during postoperative warfarin thromboprophylaxis: a second example of postorthopedic surgery ‘spontaneous' HIT. J Thromb Haemost 2009;7:499-501
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Makris M, Jay RM, Kelton JG. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. Am J Med 2008;121:632-6
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Levine MN, Hirsh J, Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003;163:2518-24
   PubMed Web of Science ®Google Scholar
• Hong AP, Cook DJ, Sigouin CS, Warkentin TE. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood 2003;101:3049-51
   PubMed Web of Science ®Google Scholar
• Girolami B, Prandoni P, Stefani PM, The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 2003;101:2955-9
   PubMed Web of Science ®Google Scholar
• Fausett MB, Vogtlander M, Lee RM, Heparin-induced thrombocytopenia is rare in pregnancy. Am J Obstet Gynecol 2001;185:148-52
   PubMed Web of Science ®Google Scholar
• Lee D, Warkentin T. Frequency of heparin induced thrombocytopenia. In: Warkentin T, Greinacher A, editors. Heparin-Induced Thrombocytopenia. 4th edition. Informa Healthcare; New York: 2007. p. 67-116
   Google Scholar
• Lubenow N, Hinz P, Thomaschewski S, The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood 2010;115:1797-803
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Sheppard JA, Sigouin CS, Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 2006;108:2937-41
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Crowther MA. When is HIT really HIT? Ann Thorac Surg 2007;83:21-3
   PubMed Web of Science ®Google Scholar
• Lillo-Le LA, Boutouyrie P, Henc-Gelas M, Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass. J Thromb Haemost 2004;2:1882-8
   PubMed Web of Science ®Google Scholar
• Cuker A, Arepally G, Crowther MA, The HIT Expert Probability (HEP) score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost 2010;8:2642-50
   PubMed Web of Science ®Google Scholar
• Messmore HL, Fabbrini N, Bird ML, Simple scoring system for early management of heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 2011;17:197-201
   PubMed Web of Science ®Google Scholar
• Lo GK, Juhl D, Warkentin TE, Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006;4:759-65
   PubMed Web of Science ®Google Scholar
• Lubenow N, Kempf R, Eichner A, Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest 2002;122:37-42
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: american College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:340S-80S
   PubMed Web of Science ®Google Scholar
• Zwicker JI, Uhl L, Huang WY, Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2004;2:2133-7
   PubMed Web of Science ®Google Scholar
• Weismann R, Tobin R. Arterial embolism occurring during systemic heparin therapy. AMA Arch Surg 1958;76:219-25
   PubMedGoogle Scholar
• Roberts B, Rosato F, Rosato E. Heparin–a cause of arterial emboli? Surgery 1964;55:803-8
   PubMed Web of Science ®Google Scholar
• Rhodes GR, Dixon RH, Silver D. Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg Gynecol Obstet 1973;136:409-16
   PubMedGoogle Scholar
• WarkentinTE, Roberts RS, Hirsh J, Kelton JG. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest. 2005 May;127(5):1857-61
   Google Scholar
• Celoria GM, Steingart RH, Banson B, Coumarin skin necrosis in a patient with heparin-induced thrombocytopenia: a case report. Angiology 1988;39:915-20
   PubMed Web of Science ®Google Scholar
• Cohen GR, Hall JC, Yeast JD, Field-Kriese D. Heparin-induced cutaneous necrosis in a postpartum patient. Obstet Gynecol 1988;72:498-9
   PubMedGoogle Scholar
• Schindewolf M, Kroll H, Ackermann H, Heparin-induced non-necrotizing skin lesions: rarely associated with heparin-induced thrombocytopenia. J Thromb Haemost 2010;8:1486-91
   PubMedGoogle Scholar
• Pouplard C, Amiral J, Borg JY, Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1999;111:700-6
   PubMed Web of Science ®Google Scholar
• Pouplard C, Leroux D, Regina S, Effectiveness of a new immunoassay for the diagnosis of heparin-induced thrombocytopenia and improved specificity when detecting IgG antibodies. Thromb Haemost 2010;103:145-50
   PubMed Web of Science ®Google Scholar
• Legnani C, Cini M, Pili C, Evaluation of a new automated panel of assays for the detection of anti-PF4/heparin antibodies in patients suspected of having heparin-induced thrombocytopenia. Thromb Haemost 2010;104:402-9
   PubMed Web of Science ®Google Scholar
• Lindhoff-Last E, Gerdsen F, Ackermann H, Bauersachs R. Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. Br J Haematol 2001;113:886-90
   PubMed Web of Science ®Google Scholar
• Suh JS, Malik MI, Aster RH, Visentin GP. Characterization of the humoral immune response in heparin-induced thrombocytopenia. Am J Hematol 1997;54:196-201
   PubMedGoogle Scholar
• Pauzner R, Greinacher A, Selleng K, False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Thromb Haemost 2009;7:1070-4
   PubMedGoogle Scholar
• Altuntas F, Matevosyan K, Burner J, Higher optical density of an antigen assay predicts thrombosis in patients with heparin-induced thrombocytopenia. Eur J Haematol 2008;80:429-35
   PubMedGoogle Scholar
• Denys B, Devreese K. A clinical-laboratory approach contributing to a rapid and reliable diagnosis of heparin-induced thrombocytopenia: an update. Thromb Res 2009;124:642-3
   PubMedGoogle Scholar
• Bakchoul T, Giptner A, Najaoui A, Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2009;7:1260-5
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Sheppard JI, Moore JC, Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 2008;6:1304-12
   PubMed Web of Science ®Google Scholar
• Ruf KM, Bensadoun ES, Davis GA, A clinical-laboratory algorithm incorporating optical density value to predict heparin-induced thrombocytopenia. Thromb Haemost 2011;105:553-9
   PubMedGoogle Scholar
• Althaus K, Strobel U, Warkentin TE, Greinacher A. Combined use of the high heparin step and optical density to optimize diagnostic sensitivity and specificity of an anti-PF4/heparin enzyme-immunoassay. Thromb Res 2011;128:256-60
   PubMed Web of Science ®Google Scholar
• Greinacher A, Potzsch B, Amiral J, Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994;71:247-51
   PubMed Web of Science ®Google Scholar
• Whitlatch NL, Perry SL, Ortel TL. Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 2008;100:678-84
   PubMedGoogle Scholar
• Whitlatch NL, Kong DF, Metjian AD, Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia. Blood 2010;116:1761-6
   PubMed Web of Science ®Google Scholar
• Bakchoul T, Giptner A, Bein G, Performance characteristics of two commercially available IgG-specific immunoassays in the assessment of heparin-induced thrombocytopenia (HIT). Thromb Res 2011;127:345-8
   PubMed Web of Science ®Google Scholar
• Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 1993;69:344-50
   PubMed Web of Science ®Google Scholar
• Jy W, Mao WW, Horstman LL, A flow cytometric assay of platelet activation marker P-selectin (CD62P) distinguishes heparin-induced thrombocytopenia (HIT) from HIT with thrombosis (HITT). Thromb Haemost 1999;82:1255-9
   PubMed Web of Science ®Google Scholar
• Morel-Kopp MC, Aboud M, Tan CW, Whole blood impedance aggregometry detects heparin-induced thrombocytopenia antibodies. Thromb Res 2010;125:e234-9
   PubMed Web of Science ®Google Scholar
• Elalamy I, Galea V, Hatmi M, Gerotziafas GT. Heparin-induced multiple electrode aggregometry: a potential tool for improvement of heparin-induced thrombocytopenia diagnosis. J Thromb Haemost 2009;7:1932-4
   PubMed Web of Science ®Google Scholar
• Lubenow N, Eichler P, Lietz T, Greinacher A. Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 2005;3:2428-36
   PubMed Web of Science ®Google Scholar
• Tardy B, Lecompte T, Boelhen F, Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood 2006;108:1492-6
   PubMed Web of Science ®Google Scholar
• Lubenow N, Eichler P, Lietz T, Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of three prospective studies. Blood 2004;104:3072-7
   PubMed Web of Science ®Google Scholar
• Lindhoff-Last E, Piechottka GP, Rabe F, Bauersachs R. Hirudin determination in plasma can be strongly influenced by the prothrombin level. Thromb Res 2000;100:55-60
   PubMed Web of Science ®Google Scholar
• Greinacher A, Warkentin TE. The direct thrombin inhibitor hirudin. Thromb Haemost 2008;99:819-29
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Greinacher A, Craven S, Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Thromb Haemost 2005;94:958-64
   PubMed Web of Science ®Google Scholar
• Kiser TH, Mann AM, Trujillo TC, Hassell KL. Evaluation of empiric versus nomogram-based direct thrombin inhibitor management in patients with suspected heparin-induced thrombocytopenia. Am J Hematol 2011;86:267-72
   PubMedGoogle Scholar
• Greinacher A, Janssens U, Berg G, Lepirudin (Recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999;100:587-93
   PubMed Web of Science ®Google Scholar
• Greinacher A, Volpel H, Janssens U, Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999;99:73-80
   PubMed Web of Science ®Google Scholar
• Greinacher A, Eichler P, Lubenow N, Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000;96:846-51
   PubMed Web of Science ®Google Scholar
• Cardenas GA, Deitcher SR. Risk of anaphylaxis after reexposure to intravenous lepirudin in patients with current or past heparin-induced thrombocytopenia. Mayo Clin Proc 2005;80:491-3
   PubMedGoogle Scholar
• Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 2003;108:2062-5
   PubMed Web of Science ®Google Scholar
• Greinacher A, Eichler P, Albrecht D, Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance. Blood 2003;101:2617-19
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Wille-Jorgensen P, Kalebo P, A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997;337:1329-35
   PubMed Web of Science ®Google Scholar
• Boyce SW, Bandyk DF, Bartholomew JR, A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis: PREVENT-HIT Study. Am J Ther 2011;18:14-22
   PubMed Web of Science ®Google Scholar
• Weitz JI, Hudoba M, Massel D, Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-91
   PubMed Web of Science ®Google Scholar
• Augoustides JG. Update in hematology: heparin-induced thrombocytopenia and bivalirudin. J Cardiothorac Vasc Anesth 2011;25:371-5
   PubMedGoogle Scholar
• Babuin L, Pengo V. Argatroban in the management of heparin-induced thrombocytopenia. Vasc Health Risk Manag 2010;6:813-19
   PubMedGoogle Scholar
• Lewis BE, Wallis DE, Berkowitz SD, Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838-43
   PubMed Web of Science ®Google Scholar
• Bartholomew JR, Pietrangeli CE, Hursting MJ. Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients. Drugs Aging 2007;24:489-99
   PubMed Web of Science ®Google Scholar
• Boggio LN, Oza VM. Argatroban use in heparin-induced thrombocytopenia. Expert Opin Pharmacother 2008;9:1963-7
   PubMed Web of Science ®Google Scholar
• Ekbatani A, Asaro LR, Malinow AM. Anticoagulation with argatroban in a parturient with heparin-induced thrombocytopenia. Int J Obstet Anesth 2010;19:82-7
   PubMed Web of Science ®Google Scholar
• Gray A, Wallis DE, Hursting MJ, Argatroban therapy for heparin-induced thrombocytopenia in acutely ill patients. Clin Appl Thromb Hemost 2007;13:353-61
   PubMed Web of Science ®Google Scholar
• Hursting MJ, Jang IK. Dosing patterns and outcomes in African American, Asian, and Hispanic patients with heparin-induced thrombocytopenia treated with argatroban. J Thromb Thrombolysis 2009;28:10-15
   PubMedGoogle Scholar
• Hursting MJ, Lewis BE, Macfarlane DE. Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 2005;11:279-87
   PubMed Web of Science ®Google Scholar
• Walenga JM, Drenth AF, Mayuga M, Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effect on coagulation factor testing. Clin Appl Thromb Hemost 2008;14:325-31
   PubMed Web of Science ®Google Scholar
• Le DT, Weibert RT, Sevilla BK, The international normalized ratio (INR) for monitoring warfarin therapy: reliability and relation to other monitoring methods. Ann Intern Med 1994;120:552-8
   PubMed Web of Science ®Google Scholar
• Alatri A, Armstrong AE, Greinacher A, Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy - an European Perspective. Thromb Res 2011; Epub ahead of print
   PubMedGoogle Scholar
• Smythe MA, Koerber JM, Forsyth LL, Argatroban dosage requirements and outcomes in intensive care versus non-intensive care patients. Pharmacotherapy 2009;29:1073-81
   PubMedGoogle Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK, Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52
   PubMed Web of Science ®Google Scholar
• Ginsberg JS, Davidson BL, Comp PC, Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;24:1-9
   PubMed Web of Science ®Google Scholar
• Wolowacz SE, Roskell NS, Plumb JM, Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 2009;101:77-85
   PubMed Web of Science ®Google Scholar
• Krauel K, Hackbarth C, Furll B, Greinacher A. Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. Blood 2012;119(5):1248-55
   PubMedGoogle Scholar
• Danhof M, de BA, Magnani HN, Stiekema JC. Pharmacokinetic considerations on Orgaran (Org 10172) therapy. Haemostasis 1992;22:73-84
   PubMedGoogle Scholar
• Chong BH, Gallus AS, Cade JF, Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study. Thromb Haemost 2001;86:1170-5
   PubMed Web of Science ®Google Scholar
• Farner B, Eichler P, Kroll H, Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 2001;85:950-7
   PubMed Web of Science ®Google Scholar
• Newman PM, Swanson RL, Chong BH. Heparin-induced thrombocytopenia: igG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Thromb Haemost 1998;80:292-7
   PubMed Web of Science ®Google Scholar
• Krauel K, Furll B, Warkentin TE, Heparin-induced thrombocytopenia–therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes. J Thromb Haemost 2008;6:2160-7
   PubMed Web of Science ®Google Scholar
• Boneu B, Necciari J, Cariou R, Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man. Thromb Haemost 1995;74:1468-73
   PubMed Web of Science ®Google Scholar
• Greinacher A, Gopinadhan M, Gunther JU, Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler Thromb Vasc Biol 2006;26:2386-93
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Cook RJ, Marder VJ, Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005;106:3791-6
   PubMed Web of Science ®Google Scholar
• Pouplard C, Couvret C, Regina S, Gruel Y. Development of antibodies specific to polyanion-modified platelet factor 4 during treatment with fondaparinux. J Thromb Haemost 2005;3:2813-15
   PubMed Web of Science ®Google Scholar
• Greinacher A. Immunogenic but Effective: the HIT-Fondaparinux brain puzzler. J Thromb Haemost 2011:Dec;9(12):2386-8
   PubMedGoogle Scholar
• Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002;162:1833-40
   PubMed Web of Science ®Google Scholar
• Bauer KA, Eriksson BI, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001;345:1305-10
   PubMed Web of Science ®Google Scholar
• Buller HR, Davidson BL, Decousus H, Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004;140:867-73
   PubMed Web of Science ®Google Scholar
• Buller HR, Davidson BL, Decousus H, Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003;349:1695-702
   PubMed Web of Science ®Google Scholar
• Wester JP, Leyte A, Oudemans-van Straaten HM, Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill. Neth J Med 2007;65:101-8
   PubMed Web of Science ®Google Scholar
• Kovacs MJ. Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux. Thromb Haemost 2005;93:999-1000
   PubMed Web of Science ®Google Scholar
• Lobo B, Finch C, Howard A, Minhas S. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost 2008;99:208-14
   PubMed Web of Science ®Google Scholar
• Grouzi E, Kyriakou E, Panagou I, Spiliotopoulou I. Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience. Clin Appl Thromb Hemost 2010;16:663-7
   PubMedGoogle Scholar
• Warkentin TE, Pai M, Sheppard JI, Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. J Thromb Haemost 2011;9:2389-96
   PubMed Web of Science ®Google Scholar
• Lassen MR, Raskob GE, Gallus A, Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009;361:594-604
   PubMed Web of Science ®Google Scholar
• Lassen MR, Raskob GE, Gallus A, Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010;375:807-15
   PubMed Web of Science ®Google Scholar
• Lassen MR, Gallus A, Raskob GE, Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010;363:2487-98
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Elavathil LJ, Hayward CP, The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997;127:804-12
   PubMed Web of Science ®Google Scholar
• Smythe MA, Warkentin TE, Stephens JL, Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. Am J Hematol 2002;71:50-2
   PubMed Web of Science ®Google Scholar
• Rice L, Attisha WK, Drexler A, Francis JL. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med 2002;136:210-15
   PubMed Web of Science ®Google Scholar
• Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 2006;355:809-17
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Lewis BE, Wildermann NM, The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol 2003;15:611-16
   PubMedGoogle Scholar
• Lewis BE, Matthai WH Jr, Cohen M, Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 2002;57:177-84
   PubMed Web of Science ®Google Scholar
• Lindhoff-Last E, Bauersachs R. Heparin-induced thrombocytopenia-alternative anticoagulation in pregnancy and lactation. Semin Thromb Hemost 2002;28:439-46
   PubMed Web of Science ®Google Scholar
• Lindhoff-Last E, Kreutzenbeck HJ, Magnani HN. Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thromb Haemost 2005;93:63-9
   PubMed Web of Science ®Google Scholar
• Schindewolf M, Magnani HN, Lindhoff-Last E. Danaparoid in pregnancy in cases of heparin intolerance - use in 59 cases. Hamostaseologie 2007;27:89-97
   PubMedGoogle Scholar
• Potzsch B, Klovekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med 2000;343:515
   PubMed Web of Science ®Google Scholar
• Matsuo T, Kusano H, Wanaka K, Heparin-induced thrombocytopenia in a uremic patient requiring hemodialysis: an alternative treatment and reexposure to heparin. Clin Appl Thromb Hemost 2007;13:182-7
   PubMedGoogle Scholar
• Wanaka K, Matsuo T, Matsuo M, Re-exposure to heparin in uremic patients requiring hemodialysis with heparin-induced thrombocytopenia. J Thromb Haemost 2010;8:616-18
   PubMedGoogle Scholar
• Nuttall GA, Oliver WC Jr, Santrach PJ, Patients with a history of type 2 heparin-induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopulmonary bypass: a prospective observational case series. Anesth Analg 2003;96:344-50
   PubMed Web of Science ®Google Scholar
• Olinger GN, Hussey CV, Olive JA, Malik MI. Cardiopulmonary bypass for patients with previously documented heparin-induced platelet aggregation. J Thorac Cardiovasc Surg 1984;87:673-7
   PubMedGoogle Scholar
• Selleng S, Lubenow N, Wollert HG, Emergency cardiopulmonary bypass in a bilaterally nephrectomized patient with a history of heparin-induced thrombocytopenia: successful reexposure to heparin. Ann Thorac Surg 2001;71:1041-2
   PubMedGoogle Scholar
• Asmis LM, Segal JB, Plantinga LC, Heparin-induced antibodies and cardiovascular risk in patients on dialysis. Thromb Haemost 2008;100:498-504
   PubMedGoogle Scholar
• Tholl U, Greinacher A, Overdick K, Anlauf M. Life-threatening anaphylactic reaction following parathyroidectomy in a dialysis patient with heparin-induced thrombocytopenia. Nephrol Dial Transplant 1997;12:2750-5
   PubMed Web of Science ®Google Scholar
• Nowak G, Bucha E, Brauns I, Czerwinski R. Anticoagulation with r-hirudin in regular haemodialysis with heparin-induced thrombocytopenia (HIT II). The first long-term application of r-hirudin in a haemodialysis patient. Wien Klin Wochenschr 1997;109:354-8
   PubMedGoogle Scholar
• O'Shea SI, Ortel TL, Kovalik EC. Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia. Semin Dial 2003;16:61-7
   PubMed Web of Science ®Google Scholar
• Fischer KG. Hemodialysis in heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-Induced Thrombocytopenia. 3rd edition. Marcel Dekker; New York: 2004. p. 509-30
   Google Scholar
• Chuang P, Parikh C, Reilly RF. A case review: anticoagulation in hemodialysis patients with heparin-induced thrombocytopenia. Am J Nephrol 2001;21:226-31
   PubMedGoogle Scholar
• Unver B, Sunder-Plassmann G, Horl WH, Apsner R. Long-term citrate anticoagulation for high-flux haemodialysis in a patient with heparin-induced thrombocytopenia type 2. Acta Med Austriaca 2002;29:146-8
   PubMedGoogle Scholar
• Fischer KG. Essentials of anticoagulation in hemodialysis. Hemodial Int 2007;11:178-89
   PubMedGoogle Scholar
• Trossaert M, Gaillard A, Commin PL, High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery. Br J Haematol 1998;101:653-5
   PubMed Web of Science ®Google Scholar
• Everett BM, Yeh R, Foo SY, Prevalence of heparin/platelet factor 4 antibodies before and after cardiac surgery. Ann Thorac Surg 2007;83:592-7
   PubMed Web of Science ®Google Scholar
• Pouplard C, May MA, Iochmann S, Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin : clinical implications for heparin-induced thrombocytopenia. Circulation 1999;99:2530-6
   PubMed Web of Science ®Google Scholar
• Selleng S, Malowsky B, Strobel U, Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive. J Thromb Haemost 2010;8:30-6
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Sheppard JA, Horsewood P, Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000;96:1703-8
   PubMed Web of Science ®Google Scholar
• Demma LJ, Levy JH. Diagnosing heparin-induced thrombocytopenia in cardiac surgical patients: not as easy as you think. Anesth Analg 2011;112:747-9
   PubMedGoogle Scholar
• Selleng S, Haneya A, Hirt S, Management of anticoagulation in patients with subacute heparin-induced thrombocytopenia scheduled for heart transplantation. Blood 2008;112:4024-7
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 2003;76:2121-31
   PubMed Web of Science ®Google Scholar
• Greinacher A, Alban S, Dummel V, Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost 1995;74:886-92
   PubMed Web of Science ®Google Scholar
• Visentin GP, Moghaddam M, Beery SE, Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. J Lab Clin Med 2001;138:22-31
   PubMed Web of Science ®Google Scholar
• Alban S, Franz G. Gas-liquid chromatography-mass spectrometry analysis of anticoagulant active curdlan sulfates. Semin Thromb Hemost 1994;20:152-8
   PubMed Web of Science ®Google Scholar
• Rosenthal MA, Rischin D, McArthur G, Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia. Ann Oncol 2002;13:770-6
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Greinacher A. Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes. Expert Opin Drug Saf 2009;8:129-44
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep 2003;2:148-57
   PubMedGoogle Scholar
• Greinacher A, Lubenow N, Hinz P, Ekkernkamp A. Heparin- induzierte thrombozytopenie. Deutsches Arzteblatt 2003;100:A2220-9
   Google Scholar
• Selleng K, Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med 2007;35:1165-76
   PubMed Web of Science ®Google Scholar